A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

BMC Cancer

Yi Hu¹  Dian-Sheng Zhong²  Qing Zhou³  Yi-Long Wu³  Jian-Hua Chen⁴  Lu Lu Yang⁵  Qiang Shi⁵  Ping Hai Zhang⁵  Yong Song⁶  Xia Song⁷  Ping Yu⁸  Zhuang Yu⁹  Guo-Sheng Feng^1,10  Gong-Yan Chen^1,11  Yi-Ping Zhang^1,12  Xin Zhang^1,13 

[1] Chinese PLA General Hospital;General Hospital of Tianjin Medical University;Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences;Hunan Cancer Hospital;Lilly Suzhou Pharmaceutical Co., Ltd;Nanjing General Hospital of Nanjing Military Command;Shanxi Cancer Hospital;Sichuan Cancer Hospital;The Affiliated Hospital of Qingdao University;The People’s Hospital of Guangxi Zhuang Autonomous Region;The Tumor Hospital affiliated to Harbin Medical University;Zhejiang Cancer Hospital;Zhongshan Hospital;

关键词: Chemotherapy;    China;    Epidermal growth factor receptor;    First-line anticancer treatment;    Non-small cell lung cancer;    Tyrosine kinase inhibitor;   

DOI  :  10.1186/s12885-017-3451-x

来源: DOAJ

【 摘 要 】

Abstract Background In recent years, systemic chemotherapy and molecular targeted therapy have become standard first-line treatments for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). The objective of this survey was to investigate first-line anticancer treatment patterns and gene aberration test status of patients with advanced nonsquamous NSCLC in China. Methods Patients included in this study had unresectable Stage IIIB/IV nonsquamous NSCLC and were admitted during August 2015 to March 2016 into one of 12 tertiary hospitals throughout China for first-line anticancer treatment. Patient data (demographics, NSCLC histologic type, Eastern Cooperative Oncology Group [ECOG] Performance Status [PS], gene aberration test and results [if performed], and first-line anticancer treatment regimen) were extracted from medical charts and entered into Medical Record Abstraction Forms (MERAFs), which were collated for analysis. Results Overall, 1041 MERAFs were collected and data from 932 MERAFs were included for analysis. Patients with unresectable Stage IIIB/IV nonsquamous NSCLC had a median age of 59 years, 56.4% were male, 58.2% were never smokers, 95.0% had adenocarcinoma, and 92.9% had an ECOG PS ≤1. A total of 665 (71.4%) patients had gene aberration tests; 46.5% (309/665) had epidermal growth factor receptor (EGFR) gene mutations, 11.5% (48/416) had anaplastic lymphoma kinase (ALK) gene fusions, and 0.8% (1/128) had a c-ros oncogene 1 gene fusion. The most common first-line treatment regimen for unresectable Stage IIIB/IV nonsquamous NSCLC was chemotherapy (72.5%, 676/932), followed by tyrosine kinase inhibitors (TKIs; 26.1%, 243/932), and TKIs plus chemotherapy (1.4%, 13/932). Most chemotherapy regimens were platinum-doublet regimens (93.5%, 631/676) and pemetrexed was the most common nonplatinum chemotherapy-backbone agent (70.2%, 443/631) in platinum-doublet regimens. Most EGFR mutation-positive patients (66.3%, 205/309) were treated with EGFR-TKIs. Conclusions Findings from our survey of 12 tertiary hospitals throughout China showed an increased rate of gene aberration testing, compared with those rates reported in previous surveys, for patients with advanced nonsquamous NSCLC. In addition, pemetrexed/platinum-doublet chemotherapy was the predominant first-line chemotherapy regimen for this population. Most patients were treated based on their gene aberration test status and results.

【 授权许可】

Unknown